Figure 3.
Depth of MRD response in peripheral blood. MRD was assessed by clonoSEQ assay (Adaptive Biotechnologies, Seattle, WA) at screening and starting with cycle 3 day 1. (A-B) Sankey plots showing changes in MRD status at a sensitivity of <1 CLL cell per 10 000 nucleated cells (<10–4). (C-D) Line graphs showing MRD response for individual patients at a sensitivity of <1 CLL cell per 1 000 000 nucleated cells (<10–6). MRD was assessed in 24 evaluable patients during 25 cycles of therapy. MRD data for 1 patient in the PV cohort are not shown because calibration did not identify a suitable dominant DNA sequence for MRD tracking. The study protocol required a lead-in cycle of pirtobrutinib monotherapy followed by 24 cycles of combination therapy with venetoclax, for a total of 25 cycles. C, cycle; D, day.

Depth of MRD response in peripheral blood. MRD was assessed by clonoSEQ assay (Adaptive Biotechnologies, Seattle, WA) at screening and starting with cycle 3 day 1. (A-B) Sankey plots showing changes in MRD status at a sensitivity of <1 CLL cell per 10 000 nucleated cells (<10–4). (C-D) Line graphs showing MRD response for individual patients at a sensitivity of <1 CLL cell per 1 000 000 nucleated cells (<10–6). MRD was assessed in 24 evaluable patients during 25 cycles of therapy. MRD data for 1 patient in the PV cohort are not shown because calibration did not identify a suitable dominant DNA sequence for MRD tracking. The study protocol required a lead-in cycle of pirtobrutinib monotherapy followed by 24 cycles of combination therapy with venetoclax, for a total of 25 cycles. C, cycle; D, day.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal